SCHEMBL6153716

SCHEMBL6153716

O=C(OCc1ccccc1)N1CCC2(CC1)c1ccccc1CS2(=O)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
CYP2C19 P33261 1/20 0.47
AVPR1A P37288 1/20 0.47
TMEM97 Q5BJF2 6/20 0.46
SIGMAR1 Q99720 6/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46
DRD1 P21728 1/20 0.46
HRH2 P25021 1/20 0.46
HTR1B P28222 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6155641 0.87 AVPR1A (0.52) MEN1KMT2ASMN1; SMN2AVPR1ASLC6A4
SCHEMBL6155020 0.82 AVPR1A (0.51) MEN1KMT2ACYP2C19AVPR1A
SCHEMBL4979567 0.77 MEN1 (0.48) KDM1AMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL4979562 0.77 MEN1 (0.48) KDM1AMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL9883693 0.77 KDM1A (0.60) KDM1AMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL25709613 0.76 MEN1 (0.58) KDM1AMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL934263 0.76 MEN1 (0.64) KDM1AMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL6154584 0.75 MEN1 (0.51) KDM1AMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL3970912 0.75 MEN1 (0.76) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL4814264 0.75 MEN1 (0.76) MEN1KMT2ANPSR1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050209262-A1 Process for producing optically active sulfoxide SANKYO COMPANY, LIMITED (JP) 2005-09-22 US disclosed
EP-1557420-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SULFOXIDE Sankyo Company, Limited (JP) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209262-A1 Process for producing optically active sulfoxide TST, TMT1A, PPOX KDM1A 3224/4885MEN1 4769/4885KMT2A 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.